← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Zen-Bio, Inc.
Rtp, NC
$15,785,529
Total funding
24
Grants
Funding over time
peak $2M · FY2005–20$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$15,785,529 · 24
By mechanism
R44$11,922,919 · 8
R43$3,343,722 · 14
R41$518,888 · 2
Investigators at Zen-Bio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Tuned stem cell extracellular vesicles are a novel chronic wound therapeutic$1,183,225
R44 · FY2020 · AG
Development of a drug discovery platform for human islets$1,072,731
R44 · FY2014 · DK
Commercialization of Human Mesothelial Cells for Research$913,158
R44 · FY2009 · RR
Selective Fyn kinase inhibitors for treatment of metabolic disease$855,351
R44 · FY2014 · DK
Tuned stem cell extracellular vesicles are a novel chronic wound therapeutic$813,686
R44 · FY2019 · AG
Development and validation of a human brown adipocyte system$777,915
R44 · FY2016 · DK
Commercialization of Human Mesothelial Cells for Research$775,235
R44 · FY2010 · RR
Development and validation of a human brown adipocyte system$721,633
R44 · FY2017 · DK
Commercialization of a Human Myocyte and Adipocyte Co-Culture System$702,268
R44 · FY2008 · DK
Development of a drug discovery platform for human islets$682,083
R44 · FY2015 · DK
Commercialization of Human Mammary Basal / Luminal Cell System for Research$681,907
R44 · FY2010 · CA
Selective Fyn kinase inhibitors for treatment of metabolic disease$643,364
R44 · FY2015 · DK
Commercialization of Human Mammary Basal / Luminal Cell System for Research$603,654
R44 · FY2011 · CA
Commercialization of a Human Myocyte and Adipocyte Co-Culture System$535,131
R44 · FY2009 · DK
Commercialization of Human Visceral Adipocytes$487,868
R44 · FY2006 · DK
Commercialization of Human Visceral Adipocytes$473,710
R44 · FY2005 · DK
Development of a Drug Discovery Platform for Human Islets$462,386
R43 · FY2012 · DK
Diabetes Therapies from Adipose Derived Stem Cells$363,202
R43 · FY2010 · DK
Selective Fyn kinase inhibitors for treatment of metabolic disease$350,681
R43 · FY2011 · DK
Identification of potent and selective GLI1 inhibitors$289,934
R41 · FY2013 · CA